Email Alert | RSS

北京大学学报（医学版） ›› 2022, Vol. 54 ›› Issue (3): 443-449. doi: 10.19723/j.issn.1671-167X.2022.03.008

• 论著 • 上一篇    下一篇

社区人群他汀干预策略预防心血管病效果的马尔可夫模型评价

巩超1,刘秋萍1,王佳敏1,刘晓非1,张明露1,杨瀚1,沈鹏2,林鸿波2,唐迅1,*(),高培1,3,*()   

  1. 1. 北京大学公共卫生学院流行病与卫生统计学系, 北京 100191
    2. 宁波市鄞州区疾病预防控制中心, 浙江宁波 315101
    3. 北京大学临床研究所真实世界证据评价中心, 北京 100191
  • 收稿日期:2022-02-07 出版日期:2022-06-18 发布日期:2022-06-14
  • 通讯作者: 唐迅,高培 E-mail:tangxun@bjmu.edu.cn;peigao@bjmu.edu.cn
  • 基金资助:
    国家自然科学基金(81973132);国家重点研发计划(2020YFC2003503)

Effectiveness of statin treatment strategies for primary prevention of cardiovascular diseases in a community-based Chinese population: A decision-analytic Markov model

Chao GONG1,Qiu-ping LIU1,Jia-min WANG1,Xiao-fei LIU1,Ming-lu ZHANG1,Han YANG1,Peng SHEN2,Hong-bo LIN2,Xun TANG1,*(),Pei GAO1,3,*()   

  1. 1. Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China
    2. Yinzhou District Center for Disease Control and Prevention, Ningbo 315101, Zhejiang, China
    3. Center of Real-World Evidence Evaluation, Peking University Clinical Research Institute, Beijing 100191, China
  • Received:2022-02-07 Online:2022-06-18 Published:2022-06-14
  • Contact: Xun TANG,Pei GAO E-mail:tangxun@bjmu.edu.cn;peigao@bjmu.edu.cn
  • Supported by:
    National Natural Sciences Foundation of China(81973132);National Key Research and Development Program of China(2020YFC2003503)

RICH HTML

 18   

PDF (PC)

147

摘要：

目的: 在中国鄞州电子健康档案研究(Chinese electronic health records research in Yinzhou, CHERRY)的队列人群中，评价西方发达国家指南普遍推荐的基于风险评估的他汀干预策略对我国发达地区人群心血管病一级预防的效果。方法: 采用马尔可夫模型比较基于风险评估的他汀干预的不同策略，具体包括：(1)不采取基于风险评估的他汀干预的常规策略，作为本研究的对照(策略0)；(2)采用2019年世界卫生组织(World Health Organization, WHO)心血管病风险评估简易模型(无实验室指标)进行风险分层，并对高危人群(风险20%及以上)进行他汀干预(策略1)；(3)采用WHO心血管病风险评估复杂模型(含实验室指标)进行风险分层，并对高危人群(风险20%及以上)进行他汀干预(策略2)；(4)采用中国动脉粥样硬化性心血管病风险预测研究(prediction for atherosclerotic cardiovascular disease risk in China, China-PAR)风险评估模型进行风险分层，并对高危人群(风险10%及以上)进行他汀干预(策略3)。在上述策略的情境下，依据指南对中危人群采取生活方式干预，高危人群采取生活方式加他汀药物干预，研究期限设为10年，马尔可夫模型的循环周期设为1年，模拟10个周期并计算心血管病事件发生数和死亡数等结局事件数，以及每预防一例心血管病事件或死亡的需干预人数(number need to treat, NNT)等效果评价指标。马尔可夫模型的参数主要来源于CHERRY队列人群、公开发表的中国人群研究数据、meta分析及系统综述。采用单因素敏感性分析探讨一般人群心血管病发病率的不确定性对结果的影响，采用概率敏感性分析探讨干预措施效应风险比参数的不确定性。结果: 纳入的225 811名基线未患心血管病的40~79岁的研究人群中，与不采取基于风险评估的他汀干预的常规策略相比，采用WHO简易模型的策略1可预防的心血管病事件为3 482例[95%不确定性区间(uncertainty interval, UI): 2 110~4 661]，采用WHO复杂模型的策略2为3 685例(95%UI: 2 255~4 912)，采用China-PAR模型的策略3为3 895例(95%UI: 2 396~5 181)。每预防一例心血管病事件使用他汀的NNT在策略1、2和3分别为22人(95%UI: 14~54)、21人(95%UI: 14~52)和27人(95%UI: 17~67)。策略3能够预防更多的心血管病事件，而策略1和2每预防一例心血管病事件使用他汀的需干预人数更少。单因素敏感性分析及概率敏感性分析的结果与主分析一致。结论: 在我国发达地区人群中采用西方国家心血管病一级预防指南普遍推荐的基于风险评估的他汀干预策略能够取得更好的健康效果；在风险评估工具的选择上，采用China-PAR模型可以获得更多的健康收益，而采用预测变量更少的WHO模型则更有效率。

关键词: 心血管病, 一级预防, 他汀, 马尔可夫模型

Abstract:

Objective: To evaluate the effectiveness of statin treatment strategies based on risk assessment for the primary prevention of cardiovascular diseases by the Western guidelines in a community-based Chinese population from economically developed areas using data from the Chinese electronic health records research in Yinzhou (CHERRY) study. Methods: A Markov model was used to evaluate the effectiveness of the following statin treatment strategies, including: (1) usual care without cardiovascular risk assessment(Strategy 0); (2) using the World Health Organization (WHO) non-laboratory-based risk charts with statin treatment for high-risk group (risk ≥ 20%) (Strategy 1); (3) using the WHO laboratory-based risk charts with statin treatment for high-risk group (risk ≥ 20%) (Strategy 2); and (4) using the Prediction for Atherosclerotic cardiovascular disease Risk in China (China-PAR) model with statin treatment for high-risk group (risk ≥ 10%, Strategy 3). According to the guidelines, adults in the medium-risk group received lifestyle intervention, and adults in the high-risk group received life-style intervention and statin treatment under these strategies. The Markov model simulated different strategies for ten years (cycles) using parameters from the CHERRY study, published data, meta-analyses and systematic reviews for Chinese. The number of cardiovascular events or deaths, as well as the number need to treat (NNT) with statin per cardiovascular event or death prevented, were calculated to compare the effectiveness of different strategies. One-way sensitivity analysis on the uncertainty of incidence rate of cardiovascular diseases, and probabilistic sensitivity analysis on the uncertainty of hazard ratios of interventions were conducted. Results: Totally 225 811 Chinese adults aged 40-79 years without cardiovascular diseases at baseline were enrolled. In contrast to the usual care without risk assessment-based statin treatment strategy, Strategy 1 using the WHO non-laboratory-based risk charts could prevent 3 482 [95% uncertainty interval (UI): 2 110-4 661] cardiovascular events, Strategy 2 using the WHO laboratory-based risk charts could prevent 3 685 (95%UI: 2 255-4 912) events, and Strategy 3 using the China-PAR model could prevent 3 895 (95%UI: 2 396-5 181) events. NNTs with statin per cardiovascular event prevented were 22 (95%UI: 14-54), 21 (95%UI: 14-52), and 27 (95%UI: 17-67), respectively. Strategy 3 could prevent more cardiovascular events, while Strategies 1 and 2 required fewer numbers need to treat with statin per cardiovascular event prevented. The results were consistent in the sensitivity analyses. Conclusion: The statin treatment strategies based on risk assessment for the primary prevention of cardiovascular diseases recommended by the Western guidelines could achieve substantive health benefits in adults from developed areas of China. Using the China-PAR model for cardiovascular risk assessment could prevent more cardiovascular diseases while using the WHO risk charts seems more efficient.

Key words: Cardiovascular diseases, Primary prevention, Statin, Markov model

中图分类号: 

  • R181.2

图1

基于马尔可夫模型的他汀干预策略的状态转换图"

表1

马尔可夫模型的效应值参数及其来源"

Items Incidence of cardiovascular diseases Mortality of cardiovascular diseases Data sources
40-49 years 50-59 years 60-69 years 70-79 years 40-49 years 50-59 years 60-69 years 70-79 years
Probability (1/100 000)
  Strategy 0, n Estimated from the current study
    Non-stratified 179 468 1 186 3 039 13 30 99 677
  Strategy 1, n Estimated from the current study
    Low risk 178 442 827 0 13 28 45 0
    Medium risk 361 667 1 305 2 448 40 49 117 458
    High risk 0 1 142 1 892 3 352 0 265 203 793
  Strategy 2, n Estimated from the current study
    Low risk 173 410 744 0 12 24 49 0
    Medium risk 687 791 1 296 2 367 67 65 107 421
    High risk 0 1 036 2 131 3 397 0 149 234 814
  Strategy 3, n Estimated from the current study
    Low risk 167 378 812 2 042 12 24 60 103
    Medium risk 449 701 1 209 2 659 40 43 96 578
    High risk 375 1 067 1 743 3 334 34 105 172 763
HR of intervention effects, ${\bar x}$±s
  Weight control 0.93±0.05 0.93±0.16 Meta-analysis[9]
  Smoking cessation 0.85±0.02 0.72±0.13 Meta-analysis[10] and cohort study[11]
  Salt reduction 0.81±0.08 0.66±0.14 Meta-analysis[12]
  Statin treatment 0.76±0.07 0.76±0.07 Clinical trial[13]

表2

研究人群的基线特征"

Characteristics Men (n=105 550) Women (n=120 261) P value
Age/years, ${\bar x}$±s 55.50 ± 9.90 54.48 ± 9.54 < 0.001
Urban, n (%) 32 394 (30.69) 39 332 (32.71) < 0.001
Smoker, n (%) 40 148 (38.04) 1 619 (1.35) < 0.001
Family history of ASCVD, n (%) 789 (0.75) 688 (0.57) < 0.001
Diabetes mellitus, n (%) 9 166 (8.68) 10 408 (8.65) 0.804
SBP/mmHg, ${\bar x}$±s 131.82 ± 15.17 130.60 ± 16.03 < 0.001
DBP/mmHg, ${\bar x}$±s 82.85 ± 9.56 81.32 ± 9.61 < 0.001
BMI/(kg/m2), ${\bar x}$±s 23.35 ± 2.68 23.23 ± 2.91 < 0.001
Waist circumference/cm, ${\bar x}$±s 83.45 ± 7.37 79.38 ± 7.73 < 0.001
Total cholesterol/(mmol/L), ${\bar x}$±s 4.80 ± 0.96 5.02 ± 0.97 < 0.001
HDL-C/(mmol/L), ${\bar x}$±s 1.25 ± 0.34 1.34 ± 0.32 < 0.001
LDL-C/(mmol/L), ${\bar x}$±s 2.77 ± 0.81 2.89 ± 0.83 < 0.001

表3

他汀干预的不同策略之间的效果比较"

Strategy 1 vs. Strategy 0 Strategy 2 vs. Strategy 0 Strategy 3 vs. Strategy 0 Strategy 2 vs. Strategy 1 Strategy 3 vs. Strategy 1 Strategy 3 vs. Strategy 2
Total numbers for assessment 225 811 225 811 225 811
Total numbers for lifestyle intervention 66 781 69 433 80 418
Total numbers for statin treatment 15 806 17 815 24 568
QALYs gained 7 570 (4 843, 9 507) 7 881 (5 120, 9 853) 7 939 (5 118, 9 966) 311 (246, 365) 369 (245, 473) 57 (-12, 114)
Cardiovascular events could be prevented 3 482 (2 110, 4 661) 3 685 (2 255, 4 912) 3 895 (2 396, 5 181) 203 (143, 254) 413 (279, 525) 211 (137, 271)
Cardiovascular deaths could be prevented 1 019 (516, 1 328) 1 044 (538, 1 356) 1 040 (523, 1 357) 25 (19, 29) 21 (8, 29) -4 (-15, 3)
All deaths could be prevented 1 230 (748, 1 554) 1 286 (800, 1 615) 1 278 (782, 1 614) 55 (45, 63) 47 (31, 61) -8 (-18, 0)
NNT with statin per cardiovas- cular event prevented 22 (14, 54) 21 (14, 52) 27 (17, 67) 0 (-2, 0) 5 (3, 14) 5 (3, 16)
NNT with statin per cardiovas- cular death prevented 66 (46, 128) 69 (48, 131) 104 (72, 205) 3 (2, 3) 38 (26, 77) 35 (24, 74)
NNT with statin per all death prevented 51 (37, 85) 52 (38, 83) 78 (56, 131) 0 (-1, 1) 26 (19, 47) 26 (18, 48)

图2

心血管病发病率的变化对心血管病事件发生数影响的单因素敏感性分析"

1 Mortensen MB , Nordestgaard BG . Statin use in primary prevention of atherosclerotic cardiovascular disease according to 5 major guidelines for sensitivity, specificity, and number needed to treat[J]. JAMA Cardiol, 2019, 4 (11): 1131- 1138.
doi: 10.1001/jamacardio.2019.3665
2 Arnett DK , Blumenthal RS , Albert MA , et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines[J]. Circulation, 2019, 140 (11): e596- e646.
3 Pearson GJ , Thanassoulis G , Anderson TJ , et al. 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults[J]. Can J Cardiol, 2021, 37 (8): 1129- 1150.
doi: 10.1016/j.cjca.2021.03.016
4 Kaptoge S , Pennells L , de Bacquer D , et al. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions[J]. Lancet Glob Health, 2019, 7 (10): e1332- e1345.
doi: 10.1016/S2214-109X(19)30318-3
5 World Health Organization . HEARTS technical package for cardiovascular disease management in primary health care: risk-based CVD management[M]. Geneva: World Health Organization, 2020: 19
6 中国心血管病风险评估和管理指南编写联合委员会. 中国心血管病风险评估和管理指南[J]. 中华预防医学杂志, 2019, (1): 13- 35.
doi: 10.3760/cma.j.issn.0253-9624.2019.01.004
7 Lin H , Tang X , Shen P , et al. Using big data to improve cardiovascular care and outcomes in China: a protocol for the Chinese electronic health records research in Yinzhou (CHERRY) study[J]. BMJ Open, 2018, 8 (2): e019698.
doi: 10.1136/bmjopen-2017-019698
8 刘秋萍, 陈汐瑾, 王佳敏, 等. 基于马尔可夫模型的社区人群心血管病筛查策略的效果评价[J]. 北京大学学报(医学版), 2021, 53 (3): 460- 466.
9 Ma C , Avenell A , Bolland M , et al. Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis[J]. BMJ, 2017, 359, j4849.
10 Tan CE , Glantz SA . Association between smoke-free legislation and hospitalizations for cardiac, cerebrovascular, and respiratory diseases[J]. Circulation, 2012, 126 (18): 2177- 2183.
doi: 10.1161/CIRCULATIONAHA.112.121301
11 Lim SH , Tai BC , Yuan JM , et al. Smoking cessation and mortality among middle-aged and elderly Chinese in Singapore: the Singapore Chinese health study[J]. Tob Control, 2013, 22 (4): 235- 240.
doi: 10.1136/tobaccocontrol-2011-050106
12 Adler AJ , Taylor F , Martin N , et al. Reduced dietary salt for the prevention of cardiovascular disease[J]. Cochrane Database Syst Rev, 2014, (12): CD009217.
13 Yusuf S , Bosch J , Dagenais G , et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease[J]. N Engl J Med, 2016, 374 (21): 2021- 2031.
doi: 10.1056/NEJMoa1600176
14 Collins R , Reith C , Emberson J , et al. Interpretation of the evidence for the efficacy and safety of statin therapy[J]. Lancet, 2016, 388 (10059): 2532- 2561.
doi: 10.1016/S0140-6736(16)31357-5
15 Pennells L , Kaptoge S , Wood A , et al. Equalization of four car-diovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies[J]. Eur Heart J, 2019, 40 (7): 621- 631.
doi: 10.1093/eurheartj/ehy653
16 Pandya A , Weinstein MC , Salomon JA , et al. Who needs laboratories and who needs statins? Comparative and cost-effectiveness analyses of non-laboratory-based, laboratory-based, and staged primary cardiovascular disease screening guidelines[J]. Circ Cardiovasc Qual Outcomes, 2014, 7 (1): 25- 32.
doi: 10.1161/CIRCOUTCOMES.113.000397
17 Zhou M , Wang H , Zeng X , et al. Mortality, morbidity, and risk factors in China and its provinces, 1990—2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394 (10204): 1145- 1158.
doi: 10.1016/S0140-6736(19)30427-1
18 Cai T , Abel L , Langford O , et al. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses[J]. BMJ, 2021, 374, n1537.
[1] 王佳敏, 刘秋萍, 张明露, 巩超, 刘舒丹, 陈暐烨, 沈鹏, 林鸿波, 高培, 唐迅. 基于马尔可夫模型的社区人群糖尿病筛查预防心血管病的效果评价[J]. 北京大学学报（医学版）, 2022, 54(3): 450-457.
[2] 刘秋萍,陈汐瑾,王佳敏,刘晓非,司亚琴,梁靖媛,沈鹏,林鸿波,唐迅,高培. 基于马尔可夫模型的社区人群心血管病筛查策略的效果评价[J]. 北京大学学报（医学版）, 2021, 53(3): 460-466.
[3] 司亚琴，唐迅，张杜丹，何柳，曹洋，王晋伟，李娜，刘建江，高培，胡永华. 北方农村人群心血管病一级预防筛查策略的评价[J]. 北京大学学报(医学版), 2018, 50(3): 443-449.
[4] 张静，任景怡，陈红，韩冠平. 他汀类药物可降低不稳定性心绞痛患者血浆中炎症相关microRNAs的表达水平[J]. 北京大学学报(医学版), 2015, 47(5): 761-768.
[5] 欧蒙恩, 张晓, 刘云松, 葛严军, 周永胜. 联合应用基质细胞衍生因子1、辛伐他汀及骨胶原支架进行体内异位成骨[J]. 北京大学学报（医学版）, 2015, 47(1): 47-51.
[6] 王艳飞, 贾新未, 赵文萍, 王凤娟, 刘亚宁, 张芳, 张丽敏, 王鸿超. 辛伐他汀后适应对缺血再灌注损伤大鼠TNF-α及NF-κB的影响[J]. 北京大学学报（医学版）, 2014, 46(6): 990-992.
[7] 徐璐, 王超, 沈文文, 祁荣. 辛伐他汀纳米脂质体对骨髓间充质干细胞成骨分化的影响[J]. 北京大学学报（医学版）, 2014, 46(6): 883-888.
[8] 关静琳, 姜雯 , 王怀宇, 曾辉, 张素敏, 王广, 毛节明. 辛伐他汀对高胆固醇血症患者血管内皮的多重影响[J]. 北京大学学报（医学版）, 2014, 46(5): 703-706.
[9] 夏经钢, 曲杨, 胡少东, 许骥, 尹春琳, 徐东. 强化调脂对行非心脏手术的冠状动脉粥样硬化性心脏病患者的心肌保护作用及机制初探[J]. 北京大学学报（医学版）, 2014, 46(4): 601-605.
[10] 翟国君, 姚伟娟, 贾子昌, 韩金涛, 赵军, 李选, 董国祥. 静脉人工血管桥内膜增生的形态学特征及洛伐他汀的干预作用[J]. 北京大学学报（医学版）, 2012, 44(5): 783-787.
[11] 杨琳, 王莹, 吕天敬, 周利群, 金杰. 临床有效剂量的洛伐他汀对前列腺癌PC3细胞的影响[J]. 北京大学学报（医学版）, 2010, 42(4): 391-395.
[12] 宋纯理, 党耕町, 贾弘抖, 郭昭庆, 马庆军. 辛伐他汀促进骨髓基质细胞的成骨分化[J]. 北京大学学报（医学版）, 2003, 35(5): 533-536.
[13] 张新超, 张彤, 徐成斌, 金晓峰. 辛伐他汀和西立伐他汀对体外培养血管平滑肌细胞增殖及迁移的影响[J]. 北京大学学报（医学版）, 2001, 33(4): 344-346.
[14] 任汉云, 张念先, 徐红, 陆道培. 辛伐他汀选择性抑制慢性髓性白血病细胞增殖并诱导凋亡[J]. 北京大学学报（医学版）, 2001, 33(2): 136-139.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 田增民, 陈涛, Nanbert ZHONG, 李志超, 尹丰, 刘爽. 神经干细胞移植治疗遗传性小脑萎缩的临床研究（英文稿）[J]. 北京大学学报（医学版）, 2009, 41(4): 456 -458 .
[2] 卢恬, 朱晓辉, 柳世庆, 郑杰, 邱晓彦. 白细胞介素2促进宫颈癌细胞系HeLaS3免疫球蛋白G的表达[J]. 北京大学学报（医学版）, 2009, 41(2): 158 -161 .
[3] 赵磊, 王天龙 . 右心室舒张末期容量监测用于肝移植术中容量管理的临床研究[J]. 北京大学学报（医学版）, 2009, 41(2): 188 -191 .
[4] 万有, , 韩济生, John E. Pintar. 孤啡肽基因敲除小鼠电针镇痛作用增强[J]. 北京大学学报（医学版）, 2009, 41(3): 376 -379 .
[5] 张燕, 韩志慧, 钟延丰, 王盛兰, 李玲玲, 郑丹枫. 骨骼肌活组织检查病理诊断技术的改进及应用[J]. 北京大学学报（医学版）, 2009, 41(4): 459 -462 .
[6] 李宏亮*, 安卫红*, 赵扬玉, 朱曦. 妊娠合并高脂血症性胰腺炎行血液净化治疗1例[J]. 北京大学学报（医学版）, 2009, 41(5): 599 -601 .
[7] 李伟军, 邢晓芳, 曲立科, 孟麟, 寿成超. PRL-3基因C104S位点突变体和CAAX缺失体的构建及表达[J]. 北京大学学报（医学版）, 2009, 41(5): 516 -520 .
[8] 丰雷, 王玉凤, 曹庆久. 哌甲酯对注意缺陷多动障碍儿童平衡功能影响的开放性研究[J]. 北京大学学报（医学版）, 2007, 39(3): 304 -309 .
[9] 汪毅, 刘粹, 王玉凤. 社会技能训练对有行为问题儿童影响的随机对照研究[J]. 北京大学学报（医学版）, 2007, 39(3): 315 -318 .
[10] 林红, 王玉凤, 吴野平. 学校生活技能教育对小学三年级学生行为问题影响的对照研究[J]. 北京大学学报（医学版）, 2007, 39(3): 319 -322 .
ISSN 1671-167X
CN 11-4691/R
主管单位：中华人民共和国教育部
主办单位：北京大学
地址： 北京市海淀区学院路38号 北京大学医学部 《北京大学学报（医学版）》
邮编：100191
电话：010-82801551
Email： xbbjb2@bjmu.edu.cn

《北京大学学报（医学版）》
微信公众号
版权所有 © 2018 《北京大学学报（医学版）》编辑部